Benzinga | Dec 20, 2021 08:34AM EST

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $2.5

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $8 to $2.5.